https://iovance-pocadmin.pixacore.com/publication/lifileucel-tumor-infiltrating-lymphocyte-cell-therapy-in-patients-with-unresectable-or-metastatic-mucosal-melanoma-after-disease-progression-on-immune-checkpoint-inhibitors/2025-07-25T05:22:29+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-one-time-autologous-tumor-infiltrating-lymphocyte-cell-therapy-in-patients-with-recurrent-and-or-metastatic-head-and-neck-squamous-cell-carcinoma/2025-09-15T09:22:27+00:00https://iovance-pocadmin.pixacore.com/publication/evaluating-curative-potential-of-lifileucel-in-previously-treated-advanced-melanoma-analyses-from-c-144-01-trial/2025-10-17T14:33:30+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-versus-ipilimumab-in-metastatic-or-unresectable-melanoma-previously-treated-with-immune-checkpoint-inhibitors-a-simulated-treatment-comparison-approach/2025-10-28T07:05:23+00:00https://iovance-pocadmin.pixacore.com/publication/evaluation-of-health-related-quality-of-life-hrqol-among-patients-treated-with-lifileucel-after-progression-on-immune-checkpoint-inhibitors-icis-and-targeted-therapies-analyses-from-the-c-144-01/2026-02-05T10:11:05+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-tumor-infiltrating-lymphocyte-therapy-with-reduced-dose-lymphodepleting-conditioning-in-high-risk-metastatic-melanoma-patients/2026-02-05T10:11:59+00:00https://iovance-pocadmin.pixacore.com/publication/real-world-evidence-based-retrospective-study-of-patients-infused-with-commercially-released-lifileucel-for-unresectable-or-metastatic-melanoma/2026-02-05T10:33:40+00:00https://iovance-pocadmin.pixacore.com/publication/real-world-evidence-based-retrospective-study-of-patients-infused-with-commercially-released-lifileucel-for-advanced-melanoma/2026-02-26T15:16:06+00:00https://iovance-pocadmin.pixacore.com/publication/enhanced-tumor-function-with-iov-5001-an-autologous-tumor-infiltrating-lymphocytes-til-engineered-with-tissue-sensing-armored-membrane-tethered-il-12/2026-03-24T18:11:06+00:00https://iovance-pocadmin.pixacore.com/publication/real-world-evidence-based-retrospective-study-of-patients-infused-with-commercially-released-lifileucel-for-advanced-melanoma-2/2026-05-06T13:42:42+00:00https://iovance-pocadmin.pixacore.com/publication/long-term-survivorship-rates-among-previously-treated-advanced-melanoma-patients-achieving-objective-response-or-with-lifileucel/2026-05-22T09:14:53+00:00https://iovance-pocadmin.pixacore.com/publication/feasibility-of-manufacturing-and-antitumor-activity-of-til-for-advanced-endometrial-cancers/2025-07-25T05:18:54+00:00https://iovance-pocadmin.pixacore.com/publication/long-term-efficacy-and-safety-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-a-5-year-analysis-of-the-c-144-01-study/2025-06-02T14:09:54+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-in-patients-with-advanced-melanoma-5-year-outcomes-of-the-c-144-01-study/2025-06-02T14:08:57+00:00https://iovance-pocadmin.pixacore.com/publication/phase-2-multicenter-study-of-the-lifileucel-regimen-and-pembrolizumab-after-frontline-platinum-doublet-chemotherapy-and-pembrolizumab-in-advanced-non-small-cell-lung-cancer/2025-06-02T10:53:47+00:00https://iovance-pocadmin.pixacore.com/publication/iov-5001-autologous-tumor-infiltrating-lymphocytes-armored-with-inducible-membrane-tethered-il-12-shows-enhanced-antitumor-efficacy-with-an-improved-cellular-state/2025-06-02T10:53:35+00:00https://iovance-pocadmin.pixacore.com/publication/tumor-infiltrating-lymphocyte-cell-therapy-for-the-treatment-of-advanced-melanoma-from-patient-identification-to-posttreatment-management-journal-of-the-advanced-practitioner-in-oncology/2025-04-18T09:28:19+00:00https://iovance-pocadmin.pixacore.com/publication/molecular-quantification-and-tumor-reactivity-assessment-of-tumor-infiltrating-lymphocytes-using-multiplexed-digital-pcr/2025-04-18T08:40:44+00:00https://iovance-pocadmin.pixacore.com/publication/a-multicenter-phase-2-trial-of-lifileucel-plus-pembrolizumab-in-patients-with-checkpoint-inhibitor-naive-metastatic-nsclc-updated-results-2/2025-04-18T08:37:46+00:00https://iovance-pocadmin.pixacore.com/publication/multimodal-single-cell-sequencing-analysis-reveals-putative-tumor-reactive-population-in-lifileucel-til-products-2/2025-04-18T08:33:47+00:00https://iovance-pocadmin.pixacore.com/publication/iov-end-201-a-phase-2-multicenter-open-label-study-of-lifileucel-tumor-infiltrating-lymphocytes-in-participants-with-previously-treated-advanced-endometrial-cancer/2025-04-18T08:32:12+00:00https://iovance-pocadmin.pixacore.com/publication/superior-anti-tumor-activity-of-il-12-engineered-til-iov-5001-in-a-simulated-tumor-microenvironment/2025-04-18T08:51:43+00:00https://iovance-pocadmin.pixacore.com/publication/multimodal-single-cell-sequencing-analysis-reveals-putative-tumor-reactive-population-in-lifileucel-til-products/2024-11-14T06:25:21+00:00https://iovance-pocadmin.pixacore.com/publication/a-multicenter-phase-2-trial-of-lifileucel-plus-pembrolizumab-in-patients-with-checkpoint-inhibitor-naive-metastatic-nsclc-updated-results/2024-11-06T15:33:23+00:00https://iovance-pocadmin.pixacore.com/publication/superior-anti-tumor-activity-of-il12-engineered-til-iov-5001-in-simulated-tumor-microenvironment/2024-11-06T15:34:05+00:00https://iovance-pocadmin.pixacore.com/publication/manufacture-and-functional-characterization-of-tumor-infiltrating-lymphocyte-product-from-endometrial-tumors/2024-10-15T09:02:26+00:00https://iovance-pocadmin.pixacore.com/publication/a-pilot-trial-of-lifileucel-for-melanoma-brain-metastases-feasibility-and-safety/2025-07-25T05:38:32+00:00https://iovance-pocadmin.pixacore.com/publication/duration-of-cytopenias-in-patients-with-advanced-melanoma-receiving-the-lifileucel-regimen-analysis-of-data-from-a-phase-2-trial/2024-10-15T09:10:16+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-lifileucel-an-autologous-tumor-infiltrating-lymphocyte-cell-therapy-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-naive-unresectable-or-metastatic-melanoma-u-2/2024-10-15T09:11:59+00:00https://iovance-pocadmin.pixacore.com/publication/tumor%e2%80%91infiltrating-lymphocytes-with-inducible-membrane%e2%80%91tethered-il%e2%80%9112-cultured-in-optimized-medium-exhibit-superior-antitumor-activity/2024-11-06T15:35:39+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-lifileucel-an-autologous-tumor-infiltrating-lymphocyte-cell-therapy-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-naive-unresectable-or-metastatic-melanoma-u/2024-09-11T08:42:58+00:00https://iovance-pocadmin.pixacore.com/publication/iov-3001-a-modified-interleukin-2-fusion-protein-for-potential-use-in-tumor-infiltrating-lymphocyte-cell-therapy-regimens/2024-09-11T08:43:00+00:00https://iovance-pocadmin.pixacore.com/publication/dynamics-of-circulating-cytokines-and-chemokines-during-and-after-tumor-infiltrating-lymphocyte-cell-therapy-with-lifileucel-in-advanced-melanoma-patients/2024-09-11T08:43:07+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-an-autologous-tumor-infiltrating-lymphocyte-monotherapy-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-immune-checkpoint-inhibitors/2024-04-11T06:59:58+00:00https://iovance-pocadmin.pixacore.com/publication/tilvance-301-a-phase-3-study-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-combination-with-pembrolizumab-vs-pembrolizumab-alone-in-treatment-naive-unresectable-or-metastatic-mela/2024-04-11T07:02:46+00:00https://iovance-pocadmin.pixacore.com/publication/multimodal-single-cell-analysis-of-lifileucel-tumor-infiltrating-lymphocyte-til-product/2024-04-11T07:13:24+00:00https://iovance-pocadmin.pixacore.com/publication/long-term-efficacy-and-patterns-of-response-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-a-4-year-analysis-of-the-c-144-01-study/2023-12-14T14:09:19+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-mucosal-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-results-from-the-phase-2-c-144-01-study/2023-12-14T14:08:39+00:00https://iovance-pocadmin.pixacore.com/publication/tilvance-301-a-phase-3-study-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-combined-with-pembrolizumab-pembro-vs-pembro-alone-in-treatment-naive-unresectable-or-metastatic-melanoma/2023-11-06T21:48:02+00:00https://iovance-pocadmin.pixacore.com/publication/tumor-infiltrating-lymphocytes-til-with-inducible-and-membrane-bound-il-12-exhibit-superior-antitumor-activity-in-vitro/2023-11-06T21:47:23+00:00https://iovance-pocadmin.pixacore.com/publication/long-term-efficacy-and-safety-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-a-4-year-analysis-of-the-c-144-01-study/2023-11-06T21:46:19+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-pts-with-advanced-mucosal-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-results-from-the-phase-2-c-144-01/2023-10-20T15:13:30+00:00https://iovance-pocadmin.pixacore.com/publication/successful-generation-of-tumor-infiltrating-lymphocytes-til-for-adoptive-cell-therapy-from-mesothelioma/2023-09-08T17:30:43+00:00https://iovance-pocadmin.pixacore.com/publication/multicenter-phase-ii-trial-of-ln-145-til-cell-therapy-plus-pembrolizumab-in-patients-with-ici-naive-metastatic-nsclc/2023-09-29T12:05:55+00:00https://iovance-pocadmin.pixacore.com/publication/a-novel-expansion-process-enhances-tumor-infiltrating-lymphocyte-til-polyfunctionality-cytotoxicity-and-expansion-while-preserving-cells-in-a-less-differentiated-and-more-stem-like-phenotype/2023-07-06T19:10:31+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-3-study-tilvance-301-to-assess-the-efficacy-and-safety-of-lifileucel-an-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-in-combination-with-pembrolizumab-com-2/2023-07-06T17:29:46+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-lifileucel-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-enrolled-in-consecutive-cohorts-of-the-c-144-01-study/2023-04-24T15:14:16+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-3-study-tilvance-301-to-assess-the-efficacy-and-safety-of-lifileucel-an-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-in-combination-with-pembrolizumab-com/2023-04-21T18:13:24+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-til-cell-monotherapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-and-targeted-therapy-pooled-analysis-of-consecutive-cohorts-c%e2%80%91144/2023-04-05T15:44:28+00:00https://iovance-pocadmin.pixacore.com/publication/immune-checkpoint-inhibitor-ici-treatment-after-progression-on-anti-pd-1-therapy-in-advanced-melanoma-a-systematic-review-of-the-literature/2023-04-05T09:56:43+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-til-cell-therapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-and-targeted-therapy-tumor-tissue-procurement-data-from-the-c-144-01-study-2/2023-04-05T09:57:40+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-til-cell-therapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-and-targeted-therapy-tumor-tissue-procurement-data-from-the-c-144-01-study/2023-04-05T09:57:20+00:00https://iovance-pocadmin.pixacore.com/publication/response-to-lifileucel-tumor%e2%80%91infiltrating-lymphocyte-til-cell-therapy-after-ici-resistance-regardless-of-definition-an-analysis-of-the-c%e2%80%91144%e2%80%9101-trial-in-patients-with-advanc/2023-04-05T09:58:13+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-and-targe/2022-12-14T19:23:14+00:00https://iovance-pocadmin.pixacore.com/publication/number-of-il-2-doses-and-clinical-outcomes-of-tumor-infiltrating-lymphocyte-til-cell-therapy-post-hoc-analysis-of-the-c-144-01-trial-of-lifileucel-in-patients-with-advanced-melanoma/2022-12-07T13:33:53+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-an-autologous-tumor-infiltrating-lymphocyte-til-cell-monotherapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-and-targeted-therapy-pooled/2022-12-06T16:34:40+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-til-cell-monotherapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-and-targeted-therapy-pooled-analysis-of-consecutive-cohorts-c-144-01-study-2/2022-11-15T22:12:48+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-til-cell-monotherapy-in-patients-with-advanced-melanoma-after-progression-on-immune-checkpoint-inhibitors-ici-and-targeted-therapy-pooled-analysis-of-consecutive-cohorts-c-144-01-study/2022-11-15T22:12:21+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-1-2-open-label-study-iov-gm1-201-of-talen-mediated-pd-1-inactivated-autologous-tumor-infiltrating-lymphocytes-til-iov-4001-in-patients-with-advanced-melanoma-an/2022-11-10T16:50:25+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-and-safety-of-lifileucel-an-investigational-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-melanoma-previously-treated-with-anti-lag3-antibody/2022-09-09T22:16:01+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-1-2-open-label-study-iov-gm1-201-of-talen-mediated-pd-1-inactivated-autologous-tumor-infiltrating-lymphocytes-til-iov-4001-in-patients-with-advanced-melanoma-and-nsclc/2022-09-09T22:16:46+00:00https://iovance-pocadmin.pixacore.com/publication/surgical-considerations-for-tumor-tissue-procurement-to-obtain-tumor-infiltrating-lymphocytes-for-adoptive-cell-therapy/2025-03-12T15:24:15+00:00https://iovance-pocadmin.pixacore.com/publication/tumor-mutational-burden-tmb-in-immune-checkpoint-inhibitor-ici-naive-and-experienced-patients-with-metastatic-melanoma-treated-with-lifileucel-a-tumor-infiltrating-lymphocyte-til-cell-therapy/2022-06-03T05:54:58+00:00https://iovance-pocadmin.pixacore.com/publication/finding-suitable-targets-is-the-major-obstacle-to-cancer-gene-therapy/2022-05-05T13:14:53+00:00https://iovance-pocadmin.pixacore.com/publication/exploiting-the-curative-potential-of-adoptive-t-cell-therapy-for-cancer/2022-05-05T13:15:06+00:00https://iovance-pocadmin.pixacore.com/publication/adoptive-cell-transfer-as-personalized-immunotherapy-for-human-cancer/2022-05-05T13:15:16+00:00https://iovance-pocadmin.pixacore.com/publication/manipulating-the-tumor-microenvironment-ex-vivo-for-enhanced-expansion-of-tumor-infiltrating-lymphocytes-for-adoptive-cell-therapy/2022-05-05T13:15:26+00:00https://iovance-pocadmin.pixacore.com/publication/redirected-lysis-assay-as-an-efficient-potency-assay-to-assess-tils-for-immunotherapy/2022-05-05T13:14:29+00:00https://iovance-pocadmin.pixacore.com/publication/remarkably-stable-tumor-infiltrating-lymphocytes-til-for-infusion-phenotype-following-cryopreservation/2022-05-05T10:14:24+00:00https://iovance-pocadmin.pixacore.com/publication/successful-expansion-and-characterization-of-tumor-infiltrating-lymphocytes-tils-from-non-melanoma-tumors/2022-05-30T05:45:36+00:00https://iovance-pocadmin.pixacore.com/publication/artificial-antigen-presenting-cells-promote-expansion-of-tumor-infiltrating-lymphocytes-tils/2022-05-24T09:15:58+00:00https://iovance-pocadmin.pixacore.com/publication/randomized-prospective-evaluation-comparing-intensity-of-lymphodepletion-before-adoptive-transfer-of-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-melanoma/2022-05-30T05:46:19+00:00https://iovance-pocadmin.pixacore.com/publication/novel-cryopreserved-tumor-infiltrating-lymphocytes-ln-144-administered-to-patients-with-metastatic-melanoma-demonstrates-efficacy-and-tolerability-in-a-multicenter-phase-2-clinical-trial/2022-05-05T07:52:07+00:00https://iovance-pocadmin.pixacore.com/publication/a-cryopreserved-tumor-infiltrating-lymphocyte-til-product-for-ln-144-generated-with-an-abbreviated-method-suitable-for-high-throughput-commercial-manufacturing-exhibits-favorable-quality-attributes/2022-05-05T07:54:42+00:00https://iovance-pocadmin.pixacore.com/publication/studies-of-key-quality-attributes-for-til-product-ln-144/2022-05-05T07:55:44+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-2-study-to-evaluate-the-safety-and-efficacy-of-using-autologous-tumor-infiltrating-lymphocytes-ln-145-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-ne/2022-05-05T07:57:24+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-2-multicenter-study-to-evaluate-the-efficacy-and-safety-of-using-autologous-tumor-infiltrating-lymphocytes-ln-145-in-patients-with-recurrent-metastatic-or-persistent-cervical-carcinoma/2022-05-05T07:58:13+00:00https://iovance-pocadmin.pixacore.com/publication/the-t-cell-growth-factor-cocktail-il-2-il-15-il-21-enhances-expansion-and-effector-function-of-tumor-infiltrating-t-cells-in-a-novel-process-developed-by-iovance/2022-05-05T07:59:43+00:00https://iovance-pocadmin.pixacore.com/publication/phenotypic-and-functional-characterization-of-tumor-infiltrating-lymphocytes-til-grown-from-non-hodgkin-lymphoma-tumors-implications-for-the-development-of-novel-therapies-for-lymphoma/2022-05-05T10:12:06+00:00https://iovance-pocadmin.pixacore.com/publication/efficacy-of-single-administration-of-tumor-infiltrating-lymphocytes-til-in-heavily-pre-treated-metastatic-melanoma-patients-following-checkpoint-therapy/2022-05-05T10:12:35+00:00https://iovance-pocadmin.pixacore.com/publication/k-channel-activation-promotes-tumor-infiltrating-lymphocyte-til-expansion-and-enhances-expression-of-ccr7/2022-05-05T08:04:16+00:00https://iovance-pocadmin.pixacore.com/publication/emigrant-tumor-infiltrating-lymphocytes-til-profoundly-differ-from-remnant-t-cells/2022-05-05T08:05:20+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-cryopreserved-autologous-tumor-infiltrating-lymphocyte-therapy-ln-144-lifileucel-in-advanced-metastatic-melanoma-patients-following-progression-on-checkpoint-inhibitors/2022-05-05T06:33:18+00:00https://iovance-pocadmin.pixacore.com/publication/pd1-positive-tumor-infiltrating-lymphocytes-til-for-the-next-generation-of-adoptive-t-cell-therapy/2022-05-05T06:33:47+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-2-multicenter-study-to-assess-the-efficacy-and-safety-of-autologous-tumor-infiltrating-lymphocytes-ln-144-for-treatment-of-patients-with-metastatic-melanoma/2022-05-30T05:34:01+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-2-multicenter-study-to-evaluate-the-efficacy-and-safety-of-autologous-tumor-infiltrating-lymphocytes-ln-145-for-the-treatment-of-patients-with-recurrent-and-or-metastatic-squamous-cell-carc/2022-05-05T06:57:48+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-to-evaluate-the-efficacy-and-safety-using-autologous-tumor-infiltrating-lymphocytes-ln-145-in-patients-with-recurrent-metastatic-or-persistent-cervi/2022-05-30T05:39:02+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-to-evaluate-the-efficacy-and-safety-using-autologous-tumor-infiltrating-lymphocytes-ln-145-in-patients-with-recurrent-metastatic-or-persistent-cervi-2/2022-05-30T05:41:59+00:00https://iovance-pocadmin.pixacore.com/publication/phase-2-study-to-assess-the-efficacy-and-safety-of-autologous-tumor-infiltrating-lymphocytes-ln-145-alone-and-in-combination-with-anti-pd-l1-inhibitor-durvalumab-medi4736-in-patients-with-locally/2022-05-05T10:10:45+00:00https://iovance-pocadmin.pixacore.com/publication/activating-ox40-receptor-promotes-the-expression-of-cd8-til-with-enhanced-t-cell-effector-function/2022-05-05T10:11:13+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-a-potential-therapy-for-metastatic-melanoma%e2%80%afpatients-who-are-primary-refractory-to-prior-anti-pd-1-therapy/2022-05-30T05:30:47+00:00https://iovance-pocadmin.pixacore.com/publication/iovance-gen-2-til-manufacturing-process-produces-drug-products-that-exhibit-favorable-quality-attributes-for-adoptive-cell-transfer-across-5-solid-tumor-indications/2022-05-05T06:13:41+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-lifileucel-ln-144-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patients-after-progression-on-multiple-therapies-independent-review-committee-data-upd/2022-05-05T06:15:52+00:00https://iovance-pocadmin.pixacore.com/publication/expanding-iovances-tumor-infiltrating-lymphocytes-til-from-core-biopsies-for-adoptive-t-cell-therapy-using-a-22-day-manufacturing-process/2022-05-05T06:18:08+00:00https://iovance-pocadmin.pixacore.com/publication/silencing-pd-1-using-ph-762-pd-1-targeting-intasyl-compound-to-improve-iovance-til-effector-function-using-gen-2-manufacturing-method/2022-05-24T02:50:09+00:00https://iovance-pocadmin.pixacore.com/publication/iovance-peripheral-blood-lymphocytes-pbl-a-potential-cell-therapy-strategy-for-the-treatment-of-chronic-lymphocytic-leukemia/2022-05-05T10:05:18+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-cryopreserved-autologous-tumor-infiltrating-lymphocyte-therapy-ln-144-lifileucel-in-advanced-metastatic-melanoma-patients-who-progressed-on-multiple-prior-therapies-including/2022-05-05T10:06:06+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-adoptive-cell-transfer-using-autologous-tumor-infiltrating-lymphocytes-ln-145-for-treatment-of-recurrent-metastatic-or-persistent-cervical-carcinoma/2022-05-05T10:06:38+00:00https://iovance-pocadmin.pixacore.com/publication/a-phase-2-study-of-autologous-tumor-infiltrating-lymphocytes-til-lifileucel-ln-144-ln-145-in-patients-with-solid-tumors/2022-05-05T10:07:10+00:00https://iovance-pocadmin.pixacore.com/publication/expansion-of-tumor-infiltrating-lymphocytes-til-using-iovances-gen-2-process-from-bladder-cancer-for-adoptive-immunotherapy/2022-05-24T02:50:28+00:00https://iovance-pocadmin.pixacore.com/publication/persistence-of-cryopreserved-tumor-infiltrating-lymphocyte-product-lifileucel-ln-144-in-c-144-01-study-of-advanced-metastatic-melanoma/2022-05-05T10:07:57+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-cryopreserved-autologous-tumor-infiltrating-lymphocyte-therapy-ln-144-lifileucel-in-advanced-metastatic-melanoma-patients-following-progression-on-checkpoint%e2%80%afinhibito/2022-05-05T10:08:26+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-tumor-infiltrating-lymphocytes-til-ln-145-in-combination-with-pembrolizumab-for-advanced-recurrent-or-metastatic-hnscc/2022-05-05T10:01:11+00:00https://iovance-pocadmin.pixacore.com/publication/in-vivo%e2%80%afpersistence-of-iovance-tumor-infiltrating-lymphocytes-ln-145-in-cervical-cancer-patients/2022-05-05T10:01:58+00:00https://iovance-pocadmin.pixacore.com/publication/genetic-modification-of-iovances-til-through-talen-mediated-knockout-of-pd-1-as-a-strategy-to-empower-til-therapy-for-cancer/2022-05-05T10:02:32+00:00https://iovance-pocadmin.pixacore.com/publication/iovance-generation-2-tumor-infiltrating-lymphocyte-til-product-is-reinvigorated-during-the-manufacturing-process/2022-05-05T10:02:59+00:00https://iovance-pocadmin.pixacore.com/publication/expert-insight-current-and-future-directions-for-tumor-infiltrating-lymphocyte-therapy-for-the-treatment-of-solid-tumors/2022-05-05T10:03:57+00:00https://iovance-pocadmin.pixacore.com/publication/long-term-follow-up-of-lifileucel-ln-144-cryopreserved-autologous-tumor-infiltrating-lymphocyte-therapy-in-patients-with-advanced-melanoma-progressed-on-multiple-prior-therapies/2022-05-05T06:09:36+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-phase-1-2-study-evaluating-the-safety-and-efficacy-of-iov-2001-an-autologous-non-genetically-modified-polyclonal-t-cell-product-in-patients-with-relapsed-or-refractory-chronic-l/2022-05-05T09:54:27+00:00https://iovance-pocadmin.pixacore.com/publication/akt-inhibition-during-ex-vivo-til-expansion-enhances-cytokine-production-and-function-while-increasing-the-population-of-less-differentiated-cd39-cd69-cd8-t-cells/2022-05-05T09:55:03+00:00https://iovance-pocadmin.pixacore.com/publication/phase-2-efficacy-and-safety-of-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-in-combination-with-pembrolizumab-in-immune-checkpoint-inhibitor-naive-patients-with-advanced-cancers/2022-05-05T09:56:08+00:00https://iovance-pocadmin.pixacore.com/publication/first-phase-2-results-of-autologous-tumor-infiltrating-lymphocyte-til-ln-145-monotherapy-in-patients-with-advanced-immune-checkpoint-inhibitor-treated-non-small-cell-lung-cancer-nsclc/2022-05-05T09:56:19+00:00https://iovance-pocadmin.pixacore.com/publication/successful-generation-of-tumor-infiltrating-lymphocyte-til-product-from-renal-cell-carcinoma-rcc-tumors-for-adoptive-cell-therapy/2022-05-05T09:56:29+00:00https://iovance-pocadmin.pixacore.com/publication/expansion-of-tumor-infiltrating-lymphocytes-til-using-static-bag-for-the-clinical-manufacturing-rapid-expansion-protocol-rep-process/2022-05-05T09:56:39+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-of-autologous-tumor-infiltrating-lymphocyte-til-ln-145-cell-therapy-in-patients-with-metastatic-non-small-cell-lung-cancer-iov-lun-202/2022-05-05T09:57:34+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-of-autologous-tumor-infiltrating-lymphocytes-til-lifileucel-ln-144-ln-145-ln-145-s1-in-patients-with-solid-tumors-iov-com-202/2022-05-05T09:58:03+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-ln-144-a-cryopreserved-autologous-tumor-infiltrating-lymphocyte-til-therapy-in-patients-with-advanced-melanoma-evaluation-of-impact-of-prior-anti-pd-1-therapy/2022-05-05T05:44:57+00:00https://iovance-pocadmin.pixacore.com/publication/safety-and-efficacy-of-lifileucel-ln-144-an-autologous-tumor-infiltrating-lymphocyte-cell-therapy-in-combination-with-pembrolizumab-for-immune-checkpoint-inhibitor-naive-patients-with-advanced-mel/2022-05-05T05:45:29+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-a-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma/2022-05-30T05:43:17+00:00https://iovance-pocadmin.pixacore.com/publication/lifileucel-ln-144-a-cryopreserved-autologous-tumor-infiltrating-lymphocyte-til-therapy-in-patients-with-advanced-unresectable-or-metastatic-melanoma-durable-duration-of-response-at-28-month-fo/2022-05-05T05:49:11+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-of-autologous-tumor-infiltrating-lymphocytes-til-ln-145-cell-therapy-in-patients-with-metastatic-non-small-cell-lung-cancer-iov-lun-202/2022-05-05T09:59:21+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-of-autologous-tumor-infiltrating-lymphocytes-til-ln-144-ln-145-ln-145-s1-in-patients-with-solid-tumors-iov-com-202/2022-05-05T09:59:42+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-1-2-study-evaluating-the-safety-and-efficacy-of-iov-2001-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll-iov/2022-05-05T10:00:12+00:00https://iovance-pocadmin.pixacore.com/publication/trial-in-progress-a-phase-2-multicenter-study-iov-lun-202-of-autologous-tumor-infiltrating-lymphocyte-til-cell-therapy-ln-145-in-patients-with-metastatic-non-small-cell-lung-cancer-mnsclc/2022-06-01T02:33:00+00:00https://iovance-pocadmin.pixacore.com/publication/preclinical-activity-and-manufacturing-feasibility-of-genetically-modified-pdcd-1-knockout-ko-tumor-infiltrating-lymphocyte-til-cell-therapy/2022-06-01T02:33:08+00:00https://iovance-pocadmin.pixacore.com/publication/successful-manufacturing-of-tumor-infiltrating-lymphocyte-til-cell-therapy-from-cryopreserved-melanoma-tumors-shipped-from-australia/2022-05-30T06:06:51+00:00https://iovance-pocadmin.pixacore.com/publication/title-of-publication-or-presentation-lorem-ipsum-dolor-sit-amet-consectetur-adipiscing-elit-sed-do-eiusmod-tempor-incididunt-ut-labore-et-dolore-magna-aliqua/2022-05-24T02:48:33+00:00